Results 91 to 100 of about 10,477 (203)

Senotherapeutics for Knee Osteoarthritis

Medicinal Research Reviews, EarlyView.
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman, Girish Pattappa, Patrick Pann, Stephan Reppenhagen, Maximilian Rudert, Peter Angele, Denitsa Docheva   +6 more
wiley   +1 more source

Effect of etanercept on cardiac function.

, 2014
(A) The effect of etanercept on LVEF. (B) The effect of etanercept on LVEDP. (C) The effect of etanercept on –dp/dx max. (D) The effect of etanercept on +dp/dx max.
Mei Yang (51996), Mei Meng (635423), Jing Zhao (21160), Jianchang Chen (316847)   +3 more
core   +1 more source

Etanercept for the treatment of rheumatoid arthritis [PDF]

, 2018
Etanercept was the first specific anticytokine therapy approved for the treatment of rheumatoid arthritis (RA). Its clinical efficacy and safety has been demonstrated by several clinical trials in early as well as established disease.
Mysler, E, Zhao, S, Robert J Moots, Zhao, S; id_orcid, Sizheng Zhao, Eduardo Mysler, Moots, R J, Moots, RJ   +7 more
core   +1 more source

Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

BMC Musculoskeletal Disorders, 2004
Background Variability in dosing and costs of biologics among patients with rheumatoid arthritis (RA) is of interest to healthcare descision-makers.
Smith Daniel, Gilbert Thomas D, Ollendorf Daniel A   +2 more
doaj  

Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of
Chunghwan Ro, Ana Ormaza Vera, Waleed Adawi, Clinton W. Enos   +3 more
wiley   +1 more source

Adjunctive etanercept reduces TB-associated pathology.

, 2013
Hematoxylin and eosin staining (20x and 200x – inset) was performed on lung tissues. Images shown are representative of sections obtained from 4 animals per group. Each time-point is shown in weeks on the individual images.
Ciaran Skerry (317997), Sanjay K. Jain (318001), Jamie Harper (317998), Mariah Klunk (317999), William R. Bishai (149943)   +4 more
core   +1 more source

Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial

Pediatric Rheumatology Online Journal
Background Etanercept has been studied in doses up to 0.8 mg/kg/week (max 50 mg/week) in juvenile idiopathic arthritis (JIA) patients. In clinical practice higher doses are used off-label, but evidence regarding the relation with outcomes is lacking.
Bastiaan T. van Dijk, Sytske Anne Bergstra, J. Merlijn van den Berg, Dieneke Schonenberg-Meinema, Lisette W.A. van Suijlekom-Smit, Marion A.J. van Rossum, Yvonne Koopman-Keemink, Rebecca ten Cate, Cornelia F. Allaart, Daniëlle M.C. Brinkman, Petra C.E. Hissink Muller   +10 more
doaj   +1 more source

Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Pediatric Rheumatology Online Journal, 2017
Background The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients with juvenile idiopathic arthritis (JIA) without systemic manifestations.
Ekaterina I. Alexeeva, Leyla S. Namazova-Baranova, Tatyana M. Bzarova, Saniya I. Valieva, Rina V. Denisova, Tatyana V. Sleptsova, Kseniya B. Isaeva, Alexandra M. Chomahidze, Nikolay I. Taibulatov, Anna N. Fetisova, Anna V. Karaseva, Alexandr A. Baranov   +11 more
doaj   +1 more source

Clinical Images: Bone Buds as Precursors to Ankylosis in Axial Spondyloarthritis

Arthritis &Rheumatology, EarlyView.
Lilach Shkolnik Arad, Gleb Slobodin
wiley   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source